2020-13656. Government-Owned Inventions; Availability for Licensing  

  • Start Preamble

    AGENCY:

    National Institutes of Health, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Licensing information may be obtained by emailing Michael Shmilovich, shmilovm@nih.gov, the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Technology description follows.

    Liposome Nanodecoys That Protect Against SARS-COV-2

    Available for licensing and commercial development are patent rights covering a liposomal vesicle (a “nanodecoy”) with a lipid bilayer with one or more proteins recognized by a pathogen (e.g., SARS-CoV-2) and one or more cytokine receptors (such as IL-6; receptors: CD126, CD130; IL-1; receptors: CD121a, CD121b, IL-8; receptors: IL-8RB; IL-12; receptors: CD212; TNF-α; receptors: CD120a, CD120b; IFN-γ; receptors: CD119, IFN-α/β; receptors: CD118) and wherein the liposomal vesicle is non-replicating. Nanodecoys that display angiotensin-converting enzyme 2 (ACE2) and multiple cytokine receptors, are able to sequester SARS-CoV-2 and inhibit viral replication and infection, as well as to mitigate COVID-19-induced cytokine release syndrome (CRS) in susceptible cells.

    Potential Commercial Applications:

    • COVID-19
    • SARS-CoV-2
    • Cytokine release syndrome

    ○ immunosuppression

    • Viral inhibition

    ○ Receptor binding competition

    Development Stage:

    • Preclinical

    Inventors: Xiaoyuan (Shawn) Chen (NIBIB) and Lang Rao (NIBIB).

    Intellectual Property: HHS Reference No. E-144-2020-0-US-01 “Engineered Cell Membrane Nanodecoys To Protect Against COVID-19;” U.S. Provisional Patent Application 63/038,380 filed June 12, 2020.

    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; shmilovm@mail.nih.gov.

    Start Signature

    Dated: June 17, 2020.

    Michael A. Shmilovich,

    Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

    End Signature End Supplemental Information

    [FR Doc. 2020-13656 Filed 6-24-20; 8:45 am]

    BILLING CODE 4140-01-P

Document Information

Published:
06/25/2020
Department:
National Institutes of Health
Entry Type:
Notice
Action:
Notice.
Document Number:
2020-13656
Pages:
38147-38147 (1 pages)
PDF File:
2020-13656.Pdf